Befetupitant (Ro67-5930) is a drug developed by Hoffmann-La Roche which acts as a potent and selective antagonist for the NK1 receptor.

[1] It was originally developed as a potential antiemetic drug, though development was ultimately discontinued after a related drug netupitant was deemed to be more suitable for clinical development.

Befetupitant has however continued to be researched for other possible applications such as treatment of corneal neovascularization.

[2] This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.